Inclusion criteria: Subjects must meet criteria for frontotemporal dementia (FTD)[1] or semantic dementia (SD)[1], be between the ages of 40-80, have had a CT or MRI of the brain 24 months prior to the screening, have a Mini Mental State Examination (MMSE) score of 15 at the screening visit and have a reliable caregiver that sees the subject regularly, is fluent in English and is able to accompany subject to all study visits. Doses of medication with the potential to effect cognition or behavior should be stable for 30 days prior to the study. Subjects should be medically stable for the past year.
Exclusion criteria: Subjects must not have been diagnosed with concurrent motor neuron disease (MND)[2], progressive nonfluent aphasia (PNFA)[1], psychiatric disorder such as psychosis or bipolar disorder, or any other neurological disorder such as stroke, Parkinson's disease (PD), seizure disorder or head injury with loss of consciousness in the past year. Subjects cannot have been treated with memantine, acetylcholinesterase inhibitors, antipsychotics, mood stabilizers, or benzodiazepines within 4 weeks of the study. Subjects may not have been treated in an investigational drug study within 60 days of screening.
